Please assess the completion status of the following clinical trial:

Trial Title: A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years at the day of consenting to the study (or at the day of randomization for cohort B patients not included in the global study)~2. Patients with OPML: at least one lesion ≥ 5 mm (Cohort A only)~3. Patients with surgically resectable HNSCC not treated with preoperative chemotherapy, pT1-4 N0-3 M0 (Cohort B only)~4. Patients with surgically resectable HNSCC not treated with preoperative chemotherapy and non-eligible to cohort B (Cohort C only)~5. PS ECOG ≤ 1~6. Treatment plan incorporating surgery and radiation therapy (or at the day of randomization for cohort B patients not included in the global study)~7. Smoker = Adult who have smoked at least 100 cigarettes in his/her lifetime (Cohort B only)~8. Current smoker (who currently smokes cigarettes every day (daily) or some days (nondaily)) or former smoker (who says he/she doesn't smoke) who stops smoking within 3 months prior to diagnosis (Cohort B only)~9. Motivation to quit smoking evaluated by the Richmond test (Cohort B only)~10. Without subordination motivation to quit smoking (Cohort B only)~11. Covered by a medical insurance~12. Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrolment~Exclusion Criteria:~1. Non-stabilized cognitive disorder~2. Synchronous malignancy (Cohort A only)~3. History of malignant disease outside the upper aerodigestive tract, except skin carcinoma~4. Substance use disorder other than smoking (cigarette and cannabis) and alcohol (Cohort B only)~5. Use of nicotine replacement therapy, bupropion, varenicline on last 3 months (Cohort B only)~6. Undergoing on last 3 months' behavioral and cognitive therapy for smoking cessation (Cohort B only)~7. Patient included in a clinical trial evaluating interventions for smoking cessation (Cohort B only)~8. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~9. Pregnant or breastfeeding woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Samples collection and Tobacco and alcohol status follow-up for patient with OPML:~Follow-up of the lesions (pictures, biopsies, brushes), malignant transformation oversight, smoking and alcohol status follow-up (questionnaires), blood and saliva samples
- Cohort B (Type: EXPERIMENTAL): Samples collection; Psychological and Sociological evaluation; Intensive and sustained smoking cessation program; Tobacco and alcohol status follow-up for patient with resectable HNSCC requiring postoperative radiotherapy or chemoradiation and which are either current smokers motivated to quit or reformed smokers within 3 months before the diagnosis of a resectable HNSCC.~Randomization 1:1, arm 1 = minimal tobacco cessation intervention, arm 2 = intensive and sustained smoking cessation program.~Smoking and alcohol status follow-up, adhesion to the smoking cessation program, tumoral follow-up, second malignant lesion, tumoral collection, blood biomarkers research
- Cohort C (Type: EXPERIMENTAL): Samples collection and Tobacco and alcohol status follow-up for patients with resectable HNSCC wich are not eligible to cohort B Smoking and alcohol status follow-up (questionnaires), tumoral follow-up, second malignant lesion and OPML lesion appearance oversight, tumoral collection, blood biomarkers research

Based on this trial design, predict the completion outcome and termination type (if applicable).